Alumis Inc. Common Stock

ALMSNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
6.51 USD
↘ 0.27 (3.98%)AT CLOSE (03:59 PM EDT)
6.41
↘ 0.10 (1.60%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
6.41
↘ 0.10 (1.60%)
🔴Market: CLOSED

Shares of Alumis Inc. Common Stock (ALMS) are trading at $6.51. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Strong Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place ALMS at a fair price relative to peers.

Technical & fundamental data as of Oct 26, 2026.

Open?$6.81
High?$6.83
Low?$6.38
Prev. Close?$6.78
Volume?1.1M
Avg. Volume?2.4M
VWAP?$6.56
Rel. Volume?0.47x
Bid / Ask
Bid?$6.30 × 200
Ask?$6.51 × 100
Spread?$0.21
Midpoint?$6.40
Valuation & Ratios
Market Cap?842.6M
Shares Out?129.4M
Float?98.3M
Float %?75.9%
P/E Ratio?N/A
P/B Ratio?1.86
EPS?-$3.39
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Neuroscience & CNS
Employees
239
Market Cap
877.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.alumis.com
Listed
2024-06-28
Address
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
4
Momentum?
10
Short Sent.?
35
Piotroski F-Score?1/9Weak
Altman Z-Score?0.26Distress
Confidence?70%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.27%High
Short Interest?11.1M
Days to Cover?4.9
Free Float98.3M
Avg Daily Volume2.3M
Settlement Date2026-10-15
Financial Health
Current Ratio?6.74Strong
Quick Ratio?6.74Strong
Cash Ratio?0.84Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
78
1.86CHEAP▾
P/S?
Peers
100
S&P
3
113.90HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
105.29HIGH▾
Returns & Efficiency
ROE?
S&P
3
-97.1%WEAK▾
ROA?
S&P
3
-78.3%WEAK▾
Cash Flow & Enterprise
FCF?$-351799000
Enterprise Value?$778.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist